Cargando…
Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathway
Targeted therapy has become the main treatment for non‐small cell lung cancer (NSCLC). Apatinib is a new antiangiogenic antitumor drug developed in China which targets vascular endothelial growth factor receptor‐2 (VEGFR‐2). We recently treated a 50‐year‐old female patient who underwent a bronchosco...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779201/ https://www.ncbi.nlm.nih.gov/pubmed/33225619 http://dx.doi.org/10.1111/1759-7714.13726 |